New drug cocktail aims to beat back stubborn leukemia

NCT ID NCT04050280

Recruiting now Disease control Sponsor: University of Maryland, Baltimore Source: ClinicalTrials.gov ↗

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests a combination of four drugs, called CLAG-GO, in adults whose acute myeloid leukemia (AML) has not responded to standard treatment or has come back after remission. Participants receive the drugs during a hospital stay, and if the cancer goes into remission, they may receive additional chemotherapy or a stem cell transplant. The goal is to see how well this combination works and what side effects it causes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CLAG-GO (cladribine, cytarabine, G-CSF, and gemtuzumab ozogamicin)
What this could lead to: If successful, this combination could offer a new treatment option for people with hard-to-treat AML, potentially leading to remission and enabling stem cell transplant.
What could go wrong: This is a phase 2 study with a small number of participants, so results may not apply to everyone. The chemotherapy combination can cause serious side effects, including infection and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA RECURRENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA RECURRENT ACUTE MYELOID LEUKEMIA, ADULT ACUTE MYELOID LEUKEMIA, RELAPSED, ADULT

Contacts and locations

Locations

University of Maryland Greenebaumn Comprehensive Cancer Center
RECRUITING

Baltimore, Maryland, 21201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.